A phase II trial of marimastat in advanced pancreatic cancer

Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy. Inhibition of matrix metalloproteinase activity involved in tumour invasion and metastases is a novel biological approach for cancer treatment. This multicentre phase II clinical trial assessed marimastat, an oral m...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, J D, Stark, A, Johnson, C D, Daniel, F, Carmichael, J, Buckels, J, Imrie, C W, Brown, P, Neoptolemos, J P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364022/
https://www.ncbi.nlm.nih.gov/pubmed/11747327
http://dx.doi.org/10.1054/bjoc.2001.2168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364022/
https://www.ncbi.nlm.nih.gov/pubmed/11747327
http://dx.doi.org/10.1054/bjoc.2001.2168

Ejemplares similares